Companies
Fate Therapeutics
iPSC-NK platform — standard batches from a single line.
- Country
- United States
FDA IND
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $205.1 million in cash, cash equivalents, and investments as of December 31, 2025 | last10k.com · metatrader.com |
| Capacity | 40,000+ square foot GMP manufacturing facility designed to support all phases of clinical development and initial commercialization | ir.fatetherapeutics.com · stocklight.com |
| Certification | Drug manufacturing license issued by the State of California, Department of Health Services, Food and Drug Branch | ir.fatetherapeutics.com |
| Regulatory approval | FDA cleared multiple Investigational New Drug (IND) applications; MHRA and EMA authorization for FT819 clinical trials | ir.fatetherapeutics.com · last10k.com |
| Production site | San Diego, California | ir.fatetherapeutics.com |
| Headcount | 161 full-time employees as of December 31, 2025 | metatrader.com |
| Revenue | $6.646 million for fiscal year 2025 | metatrader.com |
Independent sources: last10k.com · metatrader.com · stocklight.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| NK-cell & CAR-NK therapy | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.